Global Commercial Prostate Team Lead

Pfizer Oncology is focused on extending its leadership in genitourinary cancers, and we are committed to developing and delivering a broad portfolio of medicines in prostate cancer that define standards of care for patients across the treatment continuum. As we build a leading global presence in prostate, we will establish two priority prostate assets: TALZENNA and Mevrometostat. With the development and launch of TALZENNA (Talazoparib), we aspire to lead biomarker driven prostate cancer in the highly competitive poly (ADP-ribose) polymerase (PARP) inhibitor landscape. With Mevrometostat we will expand on the leadership and presence by establishing a first-in-class EZH2i in both metastatic castration-resistant prostate cancer (MCRPC) and metastatic castration-sensitive prostate cancer MCSPC in all-comer populations.

As a priority brand for the Oncology portfolio, TALZENNA in prostate cancer has the potential to deliver close to $2B in global peak revenues. We are laser focused on driving robust launch uptake of the first indication in 1L mCPRC (TALAPRO-2); approved in the U.S. in June 2023 in HRRm mCRPC, the EU in January 2024 in all-comers mCRPC, and Japan in January 2024 in BRCAm mCRPC. The Talazoparib prostate development program includes a Phase 3 study in the earlier setting of advanced prostate cancer, in combination with XTANDI for adult patients in HRRm mCSPC (TALAPRO-3).  Estimated US/EU approval in 2H 2026.

Pfizer will build on leadership in prostate cancer by launching Mevrometostat, a first in class EZH2 inhibitor that has the potential to deliver over $3B in global peak revenues. The first launch in MCRPC (MEVPRO-1) is expected in the in U.S. in 2027, with an indication expansion (MEVPRO-2) within 6-9 months after. The development program for Mevrometostat also includes Phase 3 study (MEVPRO-3) in MCSPC, in combination with XTANDI in an all-comers population. Estimated US/EU approval in 2029/2030.

ROLE SUMMARY

This role will be responsible for leading a team of global marketing colleagues to drive TALZENNA in-line mCRPC global brand strategy and deliver the global launches of TALZENNA in HRRm mCSPC and Mevrometostat in both MCRPC and MCPSC. This individual will partner closely with Global Medical Affairs, Global Access and Value, Global Value & Evidence, Global Product Development, PGS, US Marketing, International Commercial Office, Chief Marketing Office, Insight Strategy & Execution, and all other Enabling Functions.

RESPONSIBILITIES 

• Lead all global elements of in-line marketing, commercial development, and launch planning for two key priority brands in Prostate Cancer for Pfizer Oncology. 
• Chair the Talzenna Global Governance Team and lead the co-creation of the TALZENNA  global brand plan in mCRPC and core content package (e.g., core creative campaign, messaging, HCP/Patient resources)
• Responsible for delivering the global launch plan and key launch stage gates for TALAPRO-3 (HRRm mCSPC), including market development activities, biomarker testing strategy, and global launch readiness activities. 
• Responsible for delivering the global launch plan and key launch stage gates for Mevrometostat in MCRPC and MCSPC, including market development activities and global launch readiness activities. 
• Collaborate closely with U.S. Marketing Team, the International Commercial office and CoLab to ensure successful implementation of in-line brand strategies and launch preparations in markets.
• Represent the Commercial voice on the Talzenna and Mevrometostat Global Product Teams (GPT)
• Drive performance in areas of functional responsibility, optimizing Pfizer asset performance, balancing long and short-term imperatives, and contribute to overall business growth and results across relevant therapeutic areas of Pfizer. 
• It requires the ability to organize complex processes and tasks into manageable projects and establish oneself as a reliable and trusted partner for all relevant Pfizer colleagues worldwide that are working on prostate cancers.
• Ensure Pfizer's needs are met throughout each brand’s lifecycle and oversee overall therapeutic area investment and consequent returns.
• Finally, the position requires the individual to build knowledge and competency across all stages of prostate cancer, understanding alternative treatment paradigms and patient management.  By working in close alignment with other global commercial teams and their respective inline indications, this leader will drive incremental business opportunities for Pfizer.
• Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create businessimpact